Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Bevacizumab + mFOLFOX6 + SCRT for RAS Mutant Rectal Cancer
NCT05111860Phase 2Recruiting
- Sponsor
- Shanghai Minimally Invasive Surgery Center
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in rectal cancer, sponsored by Shanghai Minimally Invasive Surgery Center. Primary endpoint: Peri-operative complications at 3 months. Started Nov 2022; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05111860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111860.